Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary M Horowitz

Showing results (231-240 of 260) with videos related to

Pageof 26
Sort By:
Haematologica|August 12, 2021
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donorsDietger Niederwieser, Helen Baldomero, Nosa Bazuaye, et al.
Blood|December 9, 2008
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantationOlle Ringdén, Steven Z Pavletic, Claudio Anasetti, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
Transplantation and Cellular Therapy|March 30, 2021
Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation ProgramRiad El Fakih, Hildegard Greinix, Mickey Koh, et al.
Blood Advances|November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 StudyAndrew S Artz, Brent R Logan, Wael Saber, et al.
NEJM Evidence|February 25, 2025
Haploidentical Bone Marrow Transplantation for Sickle Cell DiseaseAdetola A Kassim, Mark C Walters, Mary Eapen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2014
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohortMukta Arora, Michael T Hemmer, Kwang Woo Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies CommitteeGhada Algwaiz, Mahmoud Aljurf, Mickey Koh, et al.
Pageof 26

Showing results (231-240 of 260) with videos related to

Sort By:
Pageof 26
Haematologica|August 12, 2021
One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donorsDietger Niederwieser, Helen Baldomero, Nosa Bazuaye, et al.
Blood|December 9, 2008
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantationOlle Ringdén, Steven Z Pavletic, Claudio Anasetti, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
Transplantation and Cellular Therapy|March 30, 2021
Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation ProgramRiad El Fakih, Hildegard Greinix, Mickey Koh, et al.
Blood Advances|November 21, 2025
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 StudyAndrew S Artz, Brent R Logan, Wael Saber, et al.
NEJM Evidence|February 25, 2025
Haploidentical Bone Marrow Transplantation for Sickle Cell DiseaseAdetola A Kassim, Mark C Walters, Mary Eapen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2014
Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohortMukta Arora, Michael T Hemmer, Kwang Woo Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2020
Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies CommitteeGhada Algwaiz, Mahmoud Aljurf, Mickey Koh, et al.
Pageof 26